JAMA Oncology

Papers
(The H4-Index of JAMA Oncology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?1518
JAMA Oncology637
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data352
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer322
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply282
Error in Text277
Errors in Key Points and Abstract259
Stargazers256
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen249
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants248
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer246
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer228
Overall Survival in the CAIRO5 Clinical Trial206
Piercing the Fog195
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers190
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses188
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults184
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades170
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab159
The Multidisciplinary Cancer Conference158
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis154
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention154
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration139
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply138
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?136
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors135
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!134
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology132
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer132
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer129
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer123
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia119
Her Defiance116
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors115
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab113
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer113
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply112
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply111
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US110
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply106
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply104
The SOUND Randomized Clinical Trial Results101
Results of the TARGET-TP Randomized Clinical Trial100
Variability in COVID-19 Vaccine Response Among People With Cancer97
An Atypical Rash on the Chest96
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?96
Immunotherapy Before Chemoradiotherapy—More Is Better?93
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply91
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation90
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer90
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers89
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 201988
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories87
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy86
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?86
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis83
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent81
Clinical Trial Diversity—Will We Know It When We See It?81
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma81
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China80
Shifting Toward Precision Oncology in SCLC Treatment80
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size80
JAMA Oncology79
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable79
Trauma79
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer79
Coding Errors in Study of Eligibility for Lung Cancer Screening78
Accelerated Approval Is Not Conditional Approval78
Error in Text77
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence75
JAMA Oncology75
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply75
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer75
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance74
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis74
0.22691893577576